Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy

International Journal of Cancer

Volumn 132, Issue 5, 2013, Pages 1022-1031

  Lattanzio, Rossano ^a   Marchisio, Marco ^a   La Sorda, Rossana ^a   Tinari, Nicola ^a   Falasca, Marco ^b   Alberti, Saverio ^a   Miscia, Sebastiano ^a   Ercolani, Cristiana ^c   Di Benedetto, Anna ^c   Perracchio, Letizia ^c   Melucci, Elisa ^c   Iacobelli, Stefano ^a   Mottolese, Marcella ^c   Natali, Pier Giorgio ^a   Piantelli, Mauro ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

breast cancer; chemotherapy; metastasis; phospholipase C 1; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHOLIPASE C GAMMA1;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; VALIDATION STUDY;

AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHOLIPASE C GAMMA; RISK FACTORS;

EID: 84872856962     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27751     Document Type: Article

References (37)

1. Botha JL, Bray F, Sankila R, et al. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003; 39: 1718-29.
2. Cianfrocca M, Goldstein LJ,. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9: 606-16.
3. Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
5. Eifel P, Axelson JA, Costa J, et al. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-89.
6. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-83.
7. Wymann MP, Schneiter R,. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008; 9: 162-76.
8. Wells A, Grandis JR,. Phospholipase C-gamma1 in tumor progression. Clin Exp Metastasis 2003; 20: 285-90.
9. Yamaguchi H, Condeelis J,. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007; 1773: 642-52.
10. Gupta GP, Massague J,. Cancer metastasis: building a framework. Cell 2006; 127: 679-95.
11. Rhee SG,. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001; 70: 281-312.
12. Kim HK, Kim JW, Zilberstein A, et al. PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell 1991; 65: 435-41.
13. Nishibe S, Wahl MI, Hernandez-Sotomayor SM, et al. Increase of the catalytic activity of phospholipase C-gamma 1 by tyrosine phosphorylation. Science 1990; 250: 1253-6.
14. Poulin B, Sekiya F, Rhee SG,. Intramolecular interaction between phosphorylated tyrosine-783 and the C-terminal Src homology 2 domain activates phospholipase C-gamma1. Proc Natl Acad Sci USA 2005; 102: 4276-81.
15. Arteaga CL, Johnson MD, Todderud G, et al. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci USA 1991; 88: 10435-9.
16. Eccles SA,. Targeting key steps in metastatic tumour progression. Curr Opin Genet Dev 2005; 15: 77-86.
17. Park JG, Lee YH, Kim SS, et al. Overexpression of phospholipase C-gamma 1 in familial adenomatous polyposis. Cancer Res 1994; 54: 2240-4.
18. Piccolo E, Innominato PF, Mariggio MA, et al. The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene 2002; 21: 6520-9.
19. Sala G, Dituri F, Raimondi C, et al. Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 2008; 68: 10187-96.
20. Shepard CR, Kassis J, Whaley DL, et al. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 2007; 26: 3020-6.
21. Querzoli P, Pedriali M, Rinaldi R, et al. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res 2006; 12: 6696-701.
22. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22: 1736-47.
23. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
24. Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
25. Sekiya F, Poulin B, Kim YJ, et al. Mechanism of tyrosine phosphorylation and activation of phospholipase C-gamma 1. Tyrosine 783 phosphorylation is not sufficient for lipase activation. J Biol Chem 2004; 279: 32181-90.
26. Faenza I, Bregoli L, Ramazzotti G, et al. Nuclear phospholipase C beta1 and cellular differentiation. Front Biosci 2008; 13: 2452-63.
27. Manzoli L, Martelli AM, Billi AM, et al. Nuclear phospholipase C: involvement in signal transduction. Prog Lipid Res 2005; 44: 185-206.
28. Ye K, Ahn JY,. Nuclear phosphoinositide signaling. Front Biosci 2008; 13: 540-8.
29. Keune W, Bultsma Y, Sommer L, et al. Phosphoinositide signalling in the nucleus. Adv Enzyme Regul 2011; 51: 91-9.
30. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science 2003; 302: 1704-9.
31. Phillips-Mason PJ, Kaur H, Burden-Gulley SM, et al. Identification of phospholipase C gamma1 as a protein tyrosine phosphatase mu substrate that regulates cell migration. J Cell Biochem 2011; 112: 39-48.
32. Li S, Wang Q, Wang Y, et al. PLC-gamma1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration. Mol Endocrinol 2009; 23: 901-13.
33. Jones NP, Katan M,. Role of phospholipase Cgamma1 in cell spreading requires association with a beta-Pix/GIT1-containing complex, leading to activation of Cdc42 and Rac1. Mol Cell Biol 2007; 27: 5790-805.
34. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-13.
35. Park SY, Lee HE, Li H, et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16: 876-87.
36. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-5.
37. Fillmore CM, Kuperwasser C,. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.